KRAS mutations also upregulate ME1 expression in hepatocellular carcinoma (HCC) [14], non-small-cell lung cancer (NSCLC) [15], and colorectal cancer (CRC) [16]. Here, KRAS is linked to hepatocellular carcinoma.